Mode
Text Size
Log in / Sign up

Structured pain assessment in post-mastectomy pain syndrome links mixed pain to multiple sources and radiotherapy

Structured pain assessment in post-mastectomy pain syndrome links mixed pain to multiple sources and…
Photo by Maria Luísa Queiroz / Unsplash
Key Takeaway
Consider multiplicity of pain sources and radiotherapy history in assessing mixed pain phenotypes.

This retrospective analysis of prospectively maintained data included 120 women with refractory post-mastectomy pain syndrome referred to a tertiary cancer-related pain clinic. The study involved a structured clinical assessment to classify pain phenotypes as nociceptive, neuropathic, or mixed, comparing these categories to identify factors associated with mixed pain. The distribution of pain phenotypes was nociceptive 40.8%, neuropathic 25.0%, and mixed 34.2%, with no significant differences reported (all p > 0.05). Multiplicity of pain sources was independently associated with mixed pain, with an adjusted odds ratio of 49.96 (95% CI 11.69–213.41). Radiotherapy-attributed pain was also independently associated with mixed pain, with an adjusted odds ratio of 5.75 (95% CI 1.15–28.82). Secondary outcomes included pain intensity, interference, and catastrophizing scores, but specific results for these were not reported. Safety and tolerability data, including adverse events and discontinuations, were not reported. Key limitations include the observational design, which precludes causal inferences, and model limitations that may affect generalizability. The authors note that results should be interpreted as hypothesis-generating, with no overstatement of causality or clinical outcomes beyond pain classification. Practice relevance suggests that mechanism-based assessment may help inform individualized management strategies, but this requires validation in prospective studies.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
IntroductionPost-mastectomy pain syndrome (PMPS) is a common and disabling complication after breast cancer surgery. Although traditionally categorized as neuropathic or nociceptive, many patients present with overlapping features consistent with mixed pain, a phenotype that remains poorly defined in clinical practice.MethodsWe performed a retrospective analysis of prospectively maintained data from women with refractory PMPS referred to a tertiary cancer-related pain clinic between January 2022 and September 2025. Pain was classified as nociceptive, neuropathic, or mixed based on structured clinical assessment. Patient-reported measures included the Brief Pain Inventory (BPI) and Pain Catastrophizing Scale (PCS). Multivariable logistic regression was used to examine factors independently associated with mixed pain.ResultsOne hundred twenty women (mean age 57.9 ± 12.5 years) were included. Pain phenotypes were nociceptive in 40.8%, neuropathic in 25.0%, and mixed in 34.2%. Pain intensity, interference, and catastrophizing scores were elevated across groups without statistically significant differences (all p > 0.05). In adjusted analyses (analytic N = 113), multiplicity of pain sources (≥2 concurrent pain generators; adjusted OR 49.96; 95% CI 11.69–213.41) and radiotherapy-attributed pain (adjusted OR 5.75; 95% CI 1.15–28.82) were independently associated with mixed pain. Model stability was evaluated in sensitivity analyses using Firth’s penalized likelihood logistic regression.ConclusionIn this tertiary cohort of women with refractory PMPS, mixed pain accounted for approximately one-third of cases and was independently associated with multiple concurrent pain sources and radiotherapy-attributed pain. These findings suggest that the coexistence of multiple pain sources, rather than pain severity alone, may characterize mixed pain presentations. Given the observational design and model limitations, results should be interpreted as hypothesis-generating. Mechanism-based assessment may help inform individualized management strategies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.